 |
 |
| October 19, 2011 |
Proteonomix, Inc. |
 |
Proteonomix, Inc. (PROT) to Move Forward With Offshore Stem Cell Testing. |
 |
MOUNTAINSIDE, NJ--(Marketwire -10/19/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it intends to move forward with the testing of its StromaCel technology through its PRTMI subsidiary or its affiliates. |
|
| Read Full Story > |
|
 |
| October 17, 2011 |
Proteonomix, Inc. |
|
Proteonomix, Inc. (PROT) Examines Licensing of Diabetes Stem Cell Technology |
|
MOUNTAINSIDE, NJ--(Marketwire -10/17/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has decided to examine the possibility of licensing its stem cell diabetes related technology to another company in light of continued progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease ("ESLD"). |
|
| Read Full Story > |
|
